Company Profile

Life Technologies (AKA: Invitrogen Corporation)
Profile last edited on: 4/21/2023      CAGE: 881X6      UEI: ----------

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

5791 Van Allen Way
Carlsbad, CA 92008
   (760) 603-7200
Location: Multiple
Congr. District: 49
County: San Diego

Public Profile

Life Technologies was formed as an amalgamation of Invitrogen and Applied Biosystems in 2008 and was acquired by Thermo Fisher Scientific Corporation in Febuary 2014. Life had also acquired 10 other small firms - several of which were also SBIR involved. The company developed, manufactured and marketed research tools in kit form. The company's kits improved gene cloning, gene expression and gene analysis techniques as well as other molecular biology activities. These techniques and activities were used to study how a cell is regulated by its genetic material, known as functional genomics, and to search for drugs that can treat diseases. The Company's kits allowed researchers to perform these activities more accurately, efficiently and with greater reproducibility than conventional research methods. On September 2000, Invitrogen merged and acquired the assets of Dexter. In October 2004, the firm acquired the UK firm DNA Research Innovations. In October 2005, firm acquired CA based Quantum Dot. also an SBIR involved firm.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Over 50M
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2000 2 NIH $673,987
Project Title: Isolation of SFV's That Regulate Transcription
2000 2 NIH $870,937
Project Title: Cloning and Expression ff Full Length Human Orfs
2000 2 NIH $850,633
Project Title: Internalization Of Peptide Fusions By Mammalian Cells
1999 1 NIH $99,456
Project Title: Interaction Dependent Secondary Infection System (ISIS)
1999 1 NIH $97,798
Project Title: Postincorporation Dye Labeling For Dna Sequencing

Key People / Management

  Gregory T Lucier -- President

  Robert P Bennett

  Jonathan D Chestnut

  David Higgins

  James P Hoeffler

  Wolfgang Kusser

  Knut R Madden

  Marijane R Russell

  Lyle Turner

Company News

Dec 24 2003
Last Minute Shopping?